Annexon (ANNX)
(Delayed Data from NSDQ)
$6.24 USD
+0.07 (1.05%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $6.25 +0.01 (0.16%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANNX 6.24 +0.07(1.05%)
Will ANNX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ANNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANNX
Is CareCloud (CCLD) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging Annexon (ANNX) This Year?
ANNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
Is Annexon (ANNX) Stock Outpacing Its Medical Peers This Year?
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Other News for ANNX
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting
Annexon spikes after updating late-stage results for lead asset against GBS
Annexon Biosciences (ANNX) Gets a Buy from TD Cowen
Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barre Syndrome at the 2024 PNS Annual Meeting